The invention relates to the use of a lectin that recognizes the fucose α 1-2 galactose unit, as a first means for labeling and optionally a second means for labelling colorectal cancer stem cells, in particular a lectin that recognizes the T antigen, in order to carry out a method for the detection and optionally isolation of colorectal cancer stem cells, a method for the detection and optionally isolation of colorectal cancer stem cells for research purposes, and a method for the in vitro diagnosis of colorectal cancer recurrence risk and/or aggressiveness so as to define a prognostic value in order to make colorectal cancer therapy adjustments, as well as a kit comprising a lectin that recognizes the fucose α 1-2 galactose unit and a lectin that recognizes the T antigen.

The invention relates to improved culture methods for expanding epithelial stem cells and obtaining organoids, to culture media involved in said methods, and to uses of said organoids.

A three dimensional cell culture and bioreactor system is provided. The system comprises one or more cell culture chamber. Each cell culture chamber comprises an inlet port and an outlet port in fluid communication with the cell culture chamber. The cell culture chambers may be segregated or in fluid communication with one another. The systems may be used to conduct drug efficacy test, isolate certain cell types from a complex tissue sample of multiple cell types, allow for the ex vivo culturing of patient tissue samples to help guide the course of treatment, and conduct co-culture experiments.

The present invention relates to a serum-free conditioned medium that solves the drawbacks mentioned in the prior art, as it does not require prior handling of the cells, and it furthermore allows starting from a large population with no additional cost. This medium favors in vitro proliferation and conservation of the pluripotency potential that allows maintaining a state that is undifferentiated with respect to the subpopulation of cancer stem cells (CSCs) and in turn does not allow survival of the differentiated cells.

There are described novel compounds of formula I: which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are each as herein defined.

##STR00001##

The invention relates to a multi-well plate comprising a support, the upper surface of which is at least partially covered with a continuous layer of a hydrogel in contact with the lower surface of a bottomless multi-well plate, the support, the continuous layer, and the bottomless multi-well plate being adhered by means of an adhesive which extends from at least certain portions of the lower surface of the bottomless multi-well plate up to certain portions of the upper surface of the support by passing through the continuous layer of hydrogel, each well of the bottomless multi-well plate being entirely surrounded by the at least certain portions of the lower surface. The application also relates to a method for preparing the multi-well plate and the use thereof for in vitro cell culture.

Methods, kits and compositions for differentiating pluripotent stem cells into cells of endothelial and hematopoietic lineages are disclosed.

The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.

The present invention relates to a method or kit for producing cancer stem cell spheroids, and a method of screening of drugs for treating cancer cell resistance using the prepared cancer stem cell spheroid, and it can conveniently produce cancer stem cell spheroids, and the prepared cancer stem cell spheroids can be effectively utilized for screening drugs for treating cancer cell resistance.

The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.